New hope for high-risk MDS: phase 3 trial of lisaftoclax combo launches
NCT ID NCT06641414
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding lisaftoclax to standard azacitidine helps people with newly diagnosed higher-risk myelodysplastic syndrome (a serious blood cancer) live longer. About 490 participants worldwide will receive either the combo or a placebo plus azacitidine. The main goal is to see if the new combination improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGHER-RISK MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100033, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact